mortality in trials review revised 2014-306730_FINAL for IRIS (1).pdf (328.73 kB)
Accounting for deaths in neonatal trials: is there a correct approach?
journal contribution
posted on 2015-02-02, 11:30 authored by Shalin A. Parekh, David J. Field, Samantha Johnson, E. Juszczak[From Introduction] The Disability and Perinatal Care report
published by the National Perinatal
Epidemiology Unit and Oxford Regional
Health Authority in 1994 emphasised
that data on the neurodevelopmental outcomes
of neonates requiring intensive care
should be formally collected.1 Over the
last 40 years, survival rates of high-risk
infants have improved but these have not
been matched with parallel improvements
in neurodevelopmental outcomes.2–4
Consequently, the focus of neonatal care
has shifted increasingly towards reducing
long-term morbidity and neurodevelopmental
impairment.1 2 Improved long-term
neurodevelopment is now considered the
‘Holy Grail’ in neonatology.1 5
These developments have led to a
change in focus of perinatal trials, which
have moved away from survival as the
primary outcome towards using long-term
functional outcomes.2 This has raised the
question of how to deal with deaths in
those trials where neurodevelopmental
impairment is of primary interest.
History
Citation
Arch Dis Child Fetal Neonatal Ed, 2015Author affiliation
/Organisation/COLLEGE OF MEDICINE, BIOLOGICAL SCIENCES AND PSYCHOLOGY/School of Medicine/Department of Health SciencesVersion
- AM (Accepted Manuscript)
Published in
Arch Dis Child Fetal Neonatal EdPublisher
BMJ Publishing Groupissn
1359-2998eissn
1468-2052Copyright date
2015Available date
2015-07-20Publisher DOI
Publisher version
http://fn.bmj.com/content/early/2015/01/20/archdischild-2014-306730Language
enAdministrator link
Usage metrics
Categories
No categories selectedKeywords
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC